Allergan’s Q2 2009 predictions remain unchanged

Allergan predicts total product net sales for the second quarter of 2009 to be between $1,050 million (726.4 million pounds) and $1,100 million.

This forecast remains unchanged from figures it released on February 4th 2009 and the assertion came after the company released its fiscal report for the first three months of the year.

For the quarter ending March 31st 2009, total product net sales decreased 6.3 per cent compared to the same period last year to $994.6 million.

Pharmaceutical net sales fell by 3.6 per cent and medical devices dropped by 17.6 per cent.

David E I Pyott, chairman of the board and chief executive of the firm, commented on the results.

He said: “Our focused approach to the management of our costs as well as our businesses has once again allowed us to deliver solid financial results for the first quarter of 2009.”

Mr Pyott added its bimatoprost ophthalmic solution called Latisse has made “excellent” progress since its launch and has received positive feedback.

Founded in 1950, Allergan now has over 8,000 employees and operates in more than 100 countries.